Silexion Therapeutics (SLXN) Competitors $7.48 +0.24 (+3.31%) Closing price 04:00 PM EasternExtended Trading$7.34 -0.15 (-1.94%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. HOTH, MTEX, SYBX, LSB, LPCN, CLDI, BLRX, LEXX, NRSN, and PRPHShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Hoth Therapeutics (HOTH), Mannatech (MTEX), Synlogic (SYBX), LakeShore Biopharma (LSB), Lipocine (LPCN), Calidi Biotherapeutics (CLDI), BioLineRx (BLRX), Lexaria Bioscience (LEXX), NeuroSense Therapeutics (NRSN), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors Hoth Therapeutics Mannatech Synlogic LakeShore Biopharma Lipocine Calidi Biotherapeutics BioLineRx Lexaria Bioscience NeuroSense Therapeutics ProPhase Labs Hoth Therapeutics (NASDAQ:HOTH) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment. Is HOTH or SLXN more profitable? Silexion Therapeutics' return on equity of 0.00% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -114.32% -105.92% Silexion Therapeutics N/A N/A -355.74% Does the media favor HOTH or SLXN? In the previous week, Silexion Therapeutics had 1 more articles in the media than Hoth Therapeutics. MarketBeat recorded 5 mentions for Silexion Therapeutics and 4 mentions for Hoth Therapeutics. Hoth Therapeutics' average media sentiment score of 1.17 beat Silexion Therapeutics' score of 0.18 indicating that Hoth Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Hoth Therapeutics Positive Silexion Therapeutics Neutral Which has stronger valuation & earnings, HOTH or SLXN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$8.19M-$1.07-1.21Silexion TherapeuticsN/AN/A-$16.44MN/AN/A Do insiders & institutionals believe in HOTH or SLXN? 7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are held by institutional investors. 6.9% of Hoth Therapeutics shares are held by company insiders. Comparatively, 6.0% of Silexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, HOTH or SLXN? Hoth Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Do analysts recommend HOTH or SLXN? Hoth Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 210.08%. Silexion Therapeutics has a consensus price target of $75.00, indicating a potential upside of 902.67%. Given Silexion Therapeutics' higher probable upside, analysts plainly believe Silexion Therapeutics is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryHoth Therapeutics beats Silexion Therapeutics on 8 of the 12 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.34M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E RatioN/A20.7630.8625.25Price / SalesN/A231.85403.9088.50Price / CashN/A41.5625.2228.45Price / Book-0.209.759.516.00Net Income-$16.44M-$54.74M$3.26B$265.34M7 Day Performance-1.58%8.09%4.49%2.81%1 Month Performance-39.77%7.70%5.18%1.50%1 Year PerformanceN/A18.13%31.98%25.46% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$7.48+3.3%$75.00+902.7%N/A$4.34MN/A0.00N/AEarnings ReportHOTHHoth Therapeutics3.0952 of 5 stars$1.25+7.8%$4.00+220.0%+81.8%$16.58MN/A-1.104Earnings ReportAnalyst ForecastShort Interest ↓MTEXMannatech0.4368 of 5 stars$8.65+8.1%N/A+21.7%$16.44M$117.87M-86.50250Earnings ReportShort Interest ↑Gap DownSYBXSynlogic0.9571 of 5 stars$1.40+1.2%N/A+2.8%$16.33M$10K-0.5680Short Interest ↑High Trading VolumeLSBLakeShore Biopharma1.5057 of 5 stars$0.79-2.2%N/A-84.1%$16.30M$85.67M0.00773News CoveragePositive NewsUpcoming EarningsShort Interest ↓Gap UpLPCNLipocine3.0306 of 5 stars$3.01+1.9%$9.00+199.5%-18.1%$16.29M$11.20M-3.4510CLDICalidi Biotherapeutics0.771 of 5 stars$5.26+4.4%N/A-71.7%$15.96MN/A0.0038Short Interest ↓BLRXBioLineRx3.3071 of 5 stars$3.68-1.1%$26.00+606.5%-87.4%$15.87M$28.94M-0.4240Earnings ReportAnalyst RevisionLEXXLexaria Bioscience3.7814 of 5 stars$0.81-1.3%$4.00+393.2%-74.2%$15.86M$460K-1.217Short Interest ↓NRSNNeuroSense Therapeutics2.5209 of 5 stars$1.15-4.6%$14.00+1,122.7%+54.5%$15.65MN/A-2.1210News CoverageAnalyst ForecastShort Interest ↑Gap DownPRPHProPhase Labs1.0738 of 5 stars$0.38+33.5%N/A-86.0%$15.25M$6.77M-0.29130Earnings ReportGap DownHigh Trading Volume Related Companies and Tools Related Companies Hoth Therapeutics Alternatives Mannatech Alternatives Synlogic Alternatives LakeShore Biopharma Alternatives Lipocine Alternatives Calidi Biotherapeutics Alternatives BioLineRx Alternatives Lexaria Bioscience Alternatives NeuroSense Therapeutics Alternatives ProPhase Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access